✦ LIBER ✦

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia

✍ Scribed by Benoit Brethon; Anne Auvrignon; Claire Galambrun; Karima Yakouben; Thierry Leblanc; Yves Bertrand; Guy Leverger; André Baruchel

Book ID: 115010816
Publisher: BioMed Central
Year: 2006
Tongue: English
Weight: 259 KB
Volume: 6
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-6-172

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final report of the efficacy and safety

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

✍ Richard A. Larson; Eric L. Sievers; Edward A. Stadtmauer; Bob Löwenberg; Elihu H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 1 views

Successful induction of molecular remiss

Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT

✍ R. Swords; P. J. Hayden; K. Molloy; M. Lawlor; P. V. Browne; P. T. Murphy 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Phase I/II study of humanized anti-CD33

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

✍ Yukio Kobayashi; Kensei Tobinai; Akihiro Takeshita; Kensuke Naito; Osamu Asai; N 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 231 KB